N,N-dimethyltryptamine and the pineal gland: Separating fact from myth
This review (2017) critically disputes the hypothesis that DMT is secreted by the pineal gland at birth, during dreaming, and at near-death to produce out-of-body experiences, in light of evidence that naturally occurring DMT concentrations in the brain are not sufficient to produce any psychoactive effects. More sound explanations for out-of-body experiences include the stress-related release of kappa-opioid receptor affine endorphins (similar to Salvinorin A) or excessive release of glutamate (similar to ketamine).
Authors
- David Nichols
Published
Abstract
The pineal gland has a romantic history, from pharaonic Egypt, where it was equated with the eye of Horus, through various religious traditions, where it was considered the seat of the soul, the third eye, etc. Recent incarnations of these notions have suggested that N,N-dimethyltryptamine is secreted by the pineal gland at birth, during dreaming, and at near death to produce out of body experiences. Scientific evidence, however, is not consistent with these ideas. The adult pineal gland weighs less than 0.2 g, and its principal function is to produce about 30 µg per day of melatonin, a hormone that regulates circadian rhythm through very high affinity interactions with melatonin receptors. It is clear that very minute concentrations of N,N-dimethyltryptamine have been detected in the brain, but they are not sufficient to produce psychoactive effects. Alternative explanations are presented to explain how stress and near death can produce altered states of consciousness without invoking the intermediacy of N,N-dimethyltryptamine.
Research Summary of 'N,N-dimethyltryptamine and the pineal gland: Separating fact from myth'
Introduction
Interest has grown in the past two decades in the idea that the pineal gland produces N,N-dimethyltryptamine (DMT) and that endogenous DMT might mediate extraordinary phenomena such as dreaming, birth, and near-death out-of-body experiences. This surge in attention was catalysed in part by Rick Strassman's popular book and documentary DMT: The Spirit Molecule, and by public presentations that revived speculation about a ‘‘DMT gland’’. The pineal gland itself has a long cultural and philosophical history as the ‘‘third eye’’ or seat of the soul, which has predisposed some authors and lay audiences to accept the idea of pineal-derived DMT as an explanation for mystical experiences. Nichols sets out to examine the scientific evidence for endogenous DMT production in humans, with a particular focus on whether the pineal gland can synthesise and release DMT in physiologically relevant amounts. The review asks whether DMT is present in the body at concentrations sufficient to affect human consciousness, evaluates biochemical and pharmacological data bearing on DMT biosynthesis and transport, and considers plausible alternative neurochemical mechanisms that could account for the phenomenology attributed to endogenous DMT. The present article was motivated by a 2017 conference presentation and takes the form of a literature synthesis rather than a systematic review with prespecified search criteria.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Compound
- Author
- APA Citation
Nichols, D. E. (2018). N,N-dimethyltryptamine and the pineal gland: Separating fact from myth. Journal of Psychopharmacology, 32(1), 30-36. https://doi.org/10.1177/0269881117736919
References (7)
Papers cited by this study that are also in Blossom
Barker, S., McIlhenny, E. H., Strassman, R. J. · Drug Testing and Analysis (2012)
Blough, B. E., Landavazo, A., Decker, A. M. et al. · Psychopharmacology (2014)
de la Torre, R., Farré, M., Roset, P. N. et al. · Annals of the New York Academy of Sciences (2006)
Frecska, E., Szabo, A., Winkelman, M. J. et al. · Translational Neurosciences (2013)
Gallimore, A. R., Strassman, R. J. · Frontiers in Pharmacology (2016)
Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A. et al. · Pharmacopsychiatry (2005)
Strassman, R. J., Qualls, C .R. · JAMA Psychiatry (1994)
Cited By (10)
Papers in Blossom that reference this study
Lawrence, D. W., Timmermann, C. · Journal of Psychoactive Drugs (2023)
Jiménez, J. H., Bouso, J. C. · Journal of Psychopharmacology (2022)
Lawrence, D. W., Carhart-Harris, R. L., Griffiths, R. R. et al. · Research Square (2022)
Barker, S. A. · Psychopharmacology (2022)
Pallavicini, C., Cavanna, F., Zamberlan, F. et al. · Journal of Psychopharmacology (2021)
Davis, A. K., Clifton, J. M., Weaver, E. G. et al. · Journal of Psychopharmacology (2020)
Martial, C., Cassol, H., Charland-Verville, V, Erowid, E. et al. · Consciousness and Cognition (2019)
Timmermann, C., Roseman, L., Williams, L. et al. · Frontiers in Psychology (2018)
Barker, S. · Frontiers in Neuroscience (2018)
Cameron, L. P. · ACS Chemical Neuroscience (2018)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.